ReviewClinical, cosmetic and investigational dermatology2026
Genetics of Vitiligo: A Review.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is a common acquired depigmentation skin disease with obvious family aggregation. About 25-50% of patients have positive family history, which belongs to polygenetic disease. In recent years, through candidate genes and genome-wide association studies, multiple susceptibility gene loci have been found, and studies also show that there is genetic heterogeneity among different populations. Environmental factors can also interact with genetic factors to trigger diseases through various mechanisms. The risk assessment model based on genetic and environmental factors provides a new direction for early screening and personalized prevention and treatment. In the future, we need to combine single cell sequencing and other multi omics technologies to explore the mechanism, develop targeted treatment strategies, and strengthen the application of genetic counseling and preventive measures in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.